中德临床肿瘤学杂志（英文版）2012，Vol.11Issue(2)：113-116,4.DOI:10.1007/s10330-011-0901-9
紫杉醇脂质体与紫杉醇联合铂类同步放化疗治疗宫颈癌的随机对照研究
A randomized controlled trial of two chemotherapy regimens - paclitaxel liposome combined with platinum and paclitaxel combined with platinum in concurrent chemoradiotherapy for cervical carcinoma
Siyuan Zeng 1Ling Li 1Meiling Zhong 1Wei Jiang 1Yun Xiao2
作者信息
- 1. Department of Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang 330006, China
- 2. Department of Radiotherapy, Jiangxi Tumor Hospital, Nanchang 330029, China
- 折叠
摘要
Abstract
Objective: The aim of the study was to compare the efficacy, side effect and influence on the survival rate of two chemotherapy regimens, paclitaxel liposome combined with platinum and paclitaxel combined with platinum, in concurrent chemoradiotherapy for cervical carcinoma. Methods: The 162 cases with primary cervical carcinoma diagnosed between January 2008 and November 2009 in Jiangxi Maternal and Child Health Hospital (China) were enrolled in this randomized controlled trial. Seventy-one cases were included in paclitaxel group and 91 in paclitaxel liposome group. And the chemotherapy doses were as follows: paclitaxel liposome and paclitaxel 135 mg/m2; cisplatin 80 mg/m2 or carboplatin AUC 4-6; then repeated every 21 days for two or three times. Radical radiotherapy was given to both groups at the same time. Efficacy was evaluated according to the tumor regression six months later and follow-up was done consistently. Results: The overall response rates of paclitaxel group and paclitaxel liposome group were 90.1% and 89 % respectively (P > 0.05). The one year cumulative survival was 91.4% for paclitaxel group and 89.2% for paclitaxel liposome group (P > 0.05). The incidence rates of adverse effects such as rash, gastrointestinal toxicity, bone marrow suppression and muscle/joint pain in paclitaxel liposome group were much lower than those in paclitaxel group (P < 0.05), while there was no difference regarding hair loss, hepatic function damage, peripheral neuritis and other aspects (P > 0.05). Conclusion: Paclitaxel liposome plus platinum is a safe and effective method for staging IIa-IV cervical carcinomas. While the long-term efficacy should be further observed.关键词
cervical cancer/ paclitaxel liposome/ paclitaxel/ platinum/ concurrent chemoradiotherapyKey words
cervical cancer/ paclitaxel liposome/ paclitaxel/ platinum/ concurrent chemoradiotherapy引用本文复制引用
Siyuan Zeng,Ling Li,Meiling Zhong ,Wei Jiang,Yun Xiao..紫杉醇脂质体与紫杉醇联合铂类同步放化疗治疗宫颈癌的随机对照研究[J].中德临床肿瘤学杂志（英文版）,2012,11(2):113-116,4.
